Biomedical and Biotechnology Research Journal (BBRJ)

BRIEF REPORT
Year
: 2020  |  Volume : 4  |  Issue : 3  |  Page : 189--192

Macrolides and COVID-19: An optimum premise


Hayder M Al-Kuraishy1, Marwa S Al-Naimi1, Claire M Lungnier2, Ali I Al-Gareeb1 
1 Department of Clinical Pharmacology, Medicine and Therapeutic, Faculty of Medical, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq
2 Mitochondria, Oxidative Stress and Muscular Protection, Institute of Physiology, Faculty of Medicine, Directeur de Recherche I CNRS Emérite, Strasbourg, France

Correspondence Address:
Prof. Hayder M Al-Kuraishy
Department of Clinical Pharmacology, Medicine and Therapeutic, Faculty of Medical, College of Medicine, Al-Mustansiriya University, Baghdad
Iraq

The epidemic of coronavirus infection disease 19 (COVID-19), which started in Wuhan City, is caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) which binds angiotensin-converting enzyme 2 (ACE2) receptor, which is highly expressed by the lung epithelial cells. In COVID-19-induced acute respiratory distress syndrome, a hyperinflammatory syndrome with hypercytokinemia leads to acute lung injury and the development of respiratory failure. Macrolides are broad-spectrum, bacteriostatic antibiotics with significant anti-inflammatory and immunomodulatory effects. Different preclinical and clinical studies have shown that macrolides inhibit cytokine release, attenuate the inflammatory response, and improve immunoglobulin response. Azithromycin potentiates the anti-SARS-CoV-2 activity of chloroquine in COVID-19. However, azithromycin alone is effective initially in the management of COVID-19 due to its antiviral and anti-inflammatory activity. The antiviral potential of azithromycin is linked to different mechanisms, including modulation of lysosomal activity and the interaction points between SARS-CoV-2 and ACE2 receptor. Therefore, macrolides, chiefly azithromycin, are an effective drug against COVID-19 through direct antiviral effect or via the modulation of hyperinflammatory status.


How to cite this article:
Al-Kuraishy HM, Al-Naimi MS, Lungnier CM, Al-Gareeb AI. Macrolides and COVID-19: An optimum premise.Biomed Biotechnol Res J 2020;4:189-192


How to cite this URL:
Al-Kuraishy HM, Al-Naimi MS, Lungnier CM, Al-Gareeb AI. Macrolides and COVID-19: An optimum premise. Biomed Biotechnol Res J [serial online] 2020 [cited 2020 Nov 27 ];4:189-192
Available from: https://www.bmbtrj.org/article.asp?issn=2588-9834;year=2020;volume=4;issue=3;spage=189;epage=192;aulast=Al-Kuraishy;type=0